Patents, Patients, and Profits: Winners and Losers in Drug Patent Challenges
Challenges to branded drugs from generic firms have benefits and costs.
Bhaven Sampat
Bhaven Sampat, PhD, is an assistant professor in the Department of Health Policy and Management at Columbia's Mailman School of Public Health. Together with Scott Hemphill, he is currently a recipient of a grant from Public Health Law Research, a national program of the Robert Wood Johnson Foundation, to study generic challenges to pharmaceutical patents. They are the authors of “When Do Generics Challenge Drug Patents?” and “Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals.”